Cargando…

Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding

Secretory leucoprotease inhibitor (SLPI) is a nonglycosylated protein produced by epithelial cells. In addition to its antiprotease activity, SLPI has been shown to exhibit antiinflammatory properties, including down-regulation of tumor necrosis factor α expression by lipopolysaccharide (LPS) in mac...

Descripción completa

Detalles Bibliográficos
Autores principales: Taggart, Clifford C., Cryan, Sally-Ann, Weldon, Sinead, Gibbons, Aileen, Greene, Catherine M., Kelly, Emer, Low, Teck Boon, O'Neill, Shane J., McElvaney, Noel G.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212970/
https://www.ncbi.nlm.nih.gov/pubmed/16352738
http://dx.doi.org/10.1084/jem.20050768
_version_ 1782148798172102656
author Taggart, Clifford C.
Cryan, Sally-Ann
Weldon, Sinead
Gibbons, Aileen
Greene, Catherine M.
Kelly, Emer
Low, Teck Boon
O'Neill, Shane J.
McElvaney, Noel G.
author_facet Taggart, Clifford C.
Cryan, Sally-Ann
Weldon, Sinead
Gibbons, Aileen
Greene, Catherine M.
Kelly, Emer
Low, Teck Boon
O'Neill, Shane J.
McElvaney, Noel G.
author_sort Taggart, Clifford C.
collection PubMed
description Secretory leucoprotease inhibitor (SLPI) is a nonglycosylated protein produced by epithelial cells. In addition to its antiprotease activity, SLPI has been shown to exhibit antiinflammatory properties, including down-regulation of tumor necrosis factor α expression by lipopolysaccharide (LPS) in macrophages and inhibition of nuclear factor (NF)-κB activation in a rat model of acute lung injury. We have previously shown that SLPI can inhibit LPS-induced NF-κB activation in monocytic cells by inhibiting degradation of IκBα without affecting the LPS-induced phosphorylation and ubiquitination of IκBα. Here, we present evidence to show that upon incubation with peripheral blood monocytes (PBMs) and the U937 monocytic cell line, SLPI enters the cells, becoming rapidly localized to the cytoplasm and nucleus, and affects NF-κB activation by binding directly to NF-κB binding sites in a site-specific manner. SLPI can also prevent p65 interaction with the NF-κB consensus region at concentrations commensurate with the physiological nuclear levels of SLPI and p65. We also demonstrate the presence of SLPI in nuclear fractions of PBMs and alveolar macrophages from individuals with cystic fibrosis and community-acquired pneumonia. Therefore, SLPI inhibition of NF-κB activation is mediated, in part, by competitive binding to the NF-κB consensus-binding site.
format Text
id pubmed-2212970
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-22129702008-03-11 Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding Taggart, Clifford C. Cryan, Sally-Ann Weldon, Sinead Gibbons, Aileen Greene, Catherine M. Kelly, Emer Low, Teck Boon O'Neill, Shane J. McElvaney, Noel G. J Exp Med Article Secretory leucoprotease inhibitor (SLPI) is a nonglycosylated protein produced by epithelial cells. In addition to its antiprotease activity, SLPI has been shown to exhibit antiinflammatory properties, including down-regulation of tumor necrosis factor α expression by lipopolysaccharide (LPS) in macrophages and inhibition of nuclear factor (NF)-κB activation in a rat model of acute lung injury. We have previously shown that SLPI can inhibit LPS-induced NF-κB activation in monocytic cells by inhibiting degradation of IκBα without affecting the LPS-induced phosphorylation and ubiquitination of IκBα. Here, we present evidence to show that upon incubation with peripheral blood monocytes (PBMs) and the U937 monocytic cell line, SLPI enters the cells, becoming rapidly localized to the cytoplasm and nucleus, and affects NF-κB activation by binding directly to NF-κB binding sites in a site-specific manner. SLPI can also prevent p65 interaction with the NF-κB consensus region at concentrations commensurate with the physiological nuclear levels of SLPI and p65. We also demonstrate the presence of SLPI in nuclear fractions of PBMs and alveolar macrophages from individuals with cystic fibrosis and community-acquired pneumonia. Therefore, SLPI inhibition of NF-κB activation is mediated, in part, by competitive binding to the NF-κB consensus-binding site. The Rockefeller University Press 2005-12-19 /pmc/articles/PMC2212970/ /pubmed/16352738 http://dx.doi.org/10.1084/jem.20050768 Text en Copyright © 2005, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Article
Taggart, Clifford C.
Cryan, Sally-Ann
Weldon, Sinead
Gibbons, Aileen
Greene, Catherine M.
Kelly, Emer
Low, Teck Boon
O'Neill, Shane J.
McElvaney, Noel G.
Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding
title Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding
title_full Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding
title_fullStr Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding
title_full_unstemmed Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding
title_short Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding
title_sort secretory leucoprotease inhibitor binds to nf-κb binding sites in monocytes and inhibits p65 binding
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212970/
https://www.ncbi.nlm.nih.gov/pubmed/16352738
http://dx.doi.org/10.1084/jem.20050768
work_keys_str_mv AT taggartcliffordc secretoryleucoproteaseinhibitorbindstonfkbbindingsitesinmonocytesandinhibitsp65binding
AT cryansallyann secretoryleucoproteaseinhibitorbindstonfkbbindingsitesinmonocytesandinhibitsp65binding
AT weldonsinead secretoryleucoproteaseinhibitorbindstonfkbbindingsitesinmonocytesandinhibitsp65binding
AT gibbonsaileen secretoryleucoproteaseinhibitorbindstonfkbbindingsitesinmonocytesandinhibitsp65binding
AT greenecatherinem secretoryleucoproteaseinhibitorbindstonfkbbindingsitesinmonocytesandinhibitsp65binding
AT kellyemer secretoryleucoproteaseinhibitorbindstonfkbbindingsitesinmonocytesandinhibitsp65binding
AT lowteckboon secretoryleucoproteaseinhibitorbindstonfkbbindingsitesinmonocytesandinhibitsp65binding
AT oneillshanej secretoryleucoproteaseinhibitorbindstonfkbbindingsitesinmonocytesandinhibitsp65binding
AT mcelvaneynoelg secretoryleucoproteaseinhibitorbindstonfkbbindingsitesinmonocytesandinhibitsp65binding